Sutro Biopharma Files 10-Q, Mentions Astellas Deal
Ticker: STRO · Form: 10-Q · Filed: May 8, 2025 · CIK: 1382101
| Field | Detail |
|---|---|
| Company | Sutro Biopharma, Inc. (STRO) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, collaboration, biotech, financials
Related Tickers: ASTL
TL;DR
Sutro Biopharma 1Q25 10-Q filed. Astellas deal details. Check financials.
AI Summary
Sutro Biopharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company's business address is 111 Oyster Point Blvd., South San Francisco, CA. Key financial reporting dates include December 31, 2024, and March 31, 2025, with a fiscal year end of December 31. The filing references a collaboration agreement with Astellas.
Why It Matters
This filing provides investors with an update on Sutro Biopharma's financial health and operational status for the first quarter of 2025, including details on its significant collaboration with Astellas.
Risk Assessment
Risk Level: medium — Biopharmaceutical companies often carry medium to high risk due to the inherent uncertainties in drug development and regulatory approvals.
Key Numbers
- 2025-03-31 — Reporting Period End (Quarterly financial data is reported as of this date.)
- 2025-05-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 1231 — Fiscal Year End (Indicates the end of the company's annual financial reporting cycle.)
Key Players & Entities
- SUTRO BIOPHARMA, INC. (company) — Filer
- 111 OYSTER POINT BLVD. (address) — Business Address
- SOUTH SAN FRANCISCO (location) — Business City
- CA (location) — Business State
- 20250331 (date) — Reporting Period End Date
- 20250508 (date) — Filing Date
- Astellas (company) — Collaboration Partner
- 2025-01-01 (date) — Astellas Collaboration Period Start
- 2025-03-31 (date) — Astellas Collaboration Period End
FAQ
What is the primary business of Sutro Biopharma, Inc.?
Sutro Biopharma, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
When is the reporting period for this 10-Q filing?
The conformed period of report for this 10-Q filing is March 31, 2025.
What is the filing date of this 10-Q?
This 10-Q filing was made as of May 8, 2025.
Does Sutro Biopharma have any significant collaborations mentioned?
Yes, the filing references a collaboration agreement with Astellas, specifically mentioning a financing component on unearned revenue related to this agreement for the period of January 1, 2024, to March 31, 2024, and a maximum period related to the agreement from March 1, 2025, to March 31, 2025.
What is Sutro Biopharma's business address?
Sutro Biopharma's business address is 111 Oyster Point Blvd., South San Francisco, CA 94080.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding SUTRO BIOPHARMA, INC. (STRO).